| Alabama Hospice Care Of Jasper 1458 Jones Dairy Road, Suite 200, Jasper, AL, 35501 | |
| (205) 385-0200 |
News Archive
Chairman of the ASMD, Alfred O. Bonati, M.D., said that, "As a physician, the results of this poll are not surprising to me. Any doctor who has ever dealt with Medicare knows that government coverage severely limits our abilities to deliver care that best fits the needs of the patient and the patient's family. We know that government coverage does not allow for flexibility, creativity, or, sometimes, even compassion."
A genetic study of childhood epilepsies has linked two new genes to severe forms of disease and provides a novel strategy for identifying therapy targets. This study used a cutting-edge genetic technique, called exome sequencing, to search for new mutations that are not inherited.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.
› Verified 4 days ago
| Name | Alabama Hospice Care Of Jasper |
|---|---|
| Location | 1458 Jones Dairy Road, Suite 200, Jasper, Alabama |
| Hospice ID | 011662 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Other |
| Profit Type | FOR PROFIT |
| SSA county code | 630 |
News Archive
Chairman of the ASMD, Alfred O. Bonati, M.D., said that, "As a physician, the results of this poll are not surprising to me. Any doctor who has ever dealt with Medicare knows that government coverage severely limits our abilities to deliver care that best fits the needs of the patient and the patient's family. We know that government coverage does not allow for flexibility, creativity, or, sometimes, even compassion."
A genetic study of childhood epilepsies has linked two new genes to severe forms of disease and provides a novel strategy for identifying therapy targets. This study used a cutting-edge genetic technique, called exome sequencing, to search for new mutations that are not inherited.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.
› Verified 4 days ago
| NPI Number | 1346542610 |
| Organization Name | Lhcg Xxii, Llc |
| Address | 1458 Jones Dairy Rd Jasper, Alabama, 35501 |
| Phone Number | (205)385-0200 |
News Archive
Chairman of the ASMD, Alfred O. Bonati, M.D., said that, "As a physician, the results of this poll are not surprising to me. Any doctor who has ever dealt with Medicare knows that government coverage severely limits our abilities to deliver care that best fits the needs of the patient and the patient's family. We know that government coverage does not allow for flexibility, creativity, or, sometimes, even compassion."
A genetic study of childhood epilepsies has linked two new genes to severe forms of disease and provides a novel strategy for identifying therapy targets. This study used a cutting-edge genetic technique, called exome sequencing, to search for new mutations that are not inherited.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.
› Verified 4 days ago
| NPI Number | 1760672638 |
| Organization Name | Hospice Complete, Inc |
| Address | 1458 Jones Dairy Rd Jasper, Alabama, 35501 |
| Phone Number | (205)385-0200 |
News Archive
Chairman of the ASMD, Alfred O. Bonati, M.D., said that, "As a physician, the results of this poll are not surprising to me. Any doctor who has ever dealt with Medicare knows that government coverage severely limits our abilities to deliver care that best fits the needs of the patient and the patient's family. We know that government coverage does not allow for flexibility, creativity, or, sometimes, even compassion."
A genetic study of childhood epilepsies has linked two new genes to severe forms of disease and provides a novel strategy for identifying therapy targets. This study used a cutting-edge genetic technique, called exome sequencing, to search for new mutations that are not inherited.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 98.4 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 99.0 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
| Patients who got timely treatment for shortness of breath | 99.4 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 97.9 | 93.3 |
News Archive
Chairman of the ASMD, Alfred O. Bonati, M.D., said that, "As a physician, the results of this poll are not surprising to me. Any doctor who has ever dealt with Medicare knows that government coverage severely limits our abilities to deliver care that best fits the needs of the patient and the patient's family. We know that government coverage does not allow for flexibility, creativity, or, sometimes, even compassion."
A genetic study of childhood epilepsies has linked two new genes to severe forms of disease and provides a novel strategy for identifying therapy targets. This study used a cutting-edge genetic technique, called exome sequencing, to search for new mutations that are not inherited.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.
› Verified 4 days ago
| Home Health Aides | 7 |
| Counselors | 1 |
| Licensed Practical or Vocational Nurses | 1 |
| Medical Social Workers | 3 |
| Physicians | 2 |
| Registered Nurses | 11 |
| Other Personnel | 4 |
| Total Employees | 29 |
|---|
News Archive
Chairman of the ASMD, Alfred O. Bonati, M.D., said that, "As a physician, the results of this poll are not surprising to me. Any doctor who has ever dealt with Medicare knows that government coverage severely limits our abilities to deliver care that best fits the needs of the patient and the patient's family. We know that government coverage does not allow for flexibility, creativity, or, sometimes, even compassion."
A genetic study of childhood epilepsies has linked two new genes to severe forms of disease and provides a novel strategy for identifying therapy targets. This study used a cutting-edge genetic technique, called exome sequencing, to search for new mutations that are not inherited.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.
› Verified 4 days ago
| Others | 2 |
| Total Volunteers | 2 |
|---|
News Archive
Chairman of the ASMD, Alfred O. Bonati, M.D., said that, "As a physician, the results of this poll are not surprising to me. Any doctor who has ever dealt with Medicare knows that government coverage severely limits our abilities to deliver care that best fits the needs of the patient and the patient's family. We know that government coverage does not allow for flexibility, creativity, or, sometimes, even compassion."
A genetic study of childhood epilepsies has linked two new genes to severe forms of disease and provides a novel strategy for identifying therapy targets. This study used a cutting-edge genetic technique, called exome sequencing, to search for new mutations that are not inherited.
BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.
Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.
› Verified 4 days ago
| Southerncare New Beacon - Jasper Location: 300 North Airport Road, Units 3 And 4, Jasper, Alabama, 35504 Phone: (205) 385-0200 |
| Alabama Hospice Care Of Jasper Location: 1458 Jones Dairy Road, Suite 200, Jasper, Alabama, 35501 Phone: (205) 385-0200 |
| Southeast Hospice Network, Llc Location: 4330 Highway 78e, Suite 120-121, Jasper, Alabama, 35501 Phone: (205) 385-0200 |